30 closest matches · ranked by relevance
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Neoplasms
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 4; 4; 4; 4 Participants
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Solid Tumors · Cancer
Primary: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21 — 2; 6; 0; 6 Subjects
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Advanced Solid Tumors · Advanced Recurrent Ovarian Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Part 1 — 0; 0; 1; 1 participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Advanced Solid Tumors
Primary: Objective Response Rate (ORR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Escalation and Dose Expansion Phases) — 0…
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Advanced Solid Tumors
Primary: Determination of the Maximum Tolerated Dose — 1.0 mg/m^2
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 4; 3; 13; 3 Participants
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
Neoplasm Metastasis
Primary: Pharmacokinetic Parameter of Maximum (Peak) Observed Serum Concentration (Cmax) Following Treatment With DS-8201a and Ritonavir - Cohort 1 — 133; 140; 121; 126 ug/mL
Cervical · Ovarian · Lung
Primary: Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition — 71.9 percent increase sestamibi retention
Advanced or Metastatic Solid Tumors
Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309
Neoplasms With Mesothelin Expression · Epithelioid Mesothelioma · Cholangiocarcinoma, Extrahepatic
Primary: Maximum Tolerated Dose (MTD) of LMB-100 With Tofacitinib — 100 mcg/kg given days 4, 6, 8 every cycle
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared